Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection (MCC/CC)

Reckitt Benckiser

Status and phase: Completed; Phase 2

Conditions: Acute Respiratory Infection

Treatments: Drug: Placebo; Drug: Mucinex

Study type: Interventional

Funder types: Industry

Identifiers

NCT01114581

2010-MUC-01

Details and patient eligibility

About

The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.

Enrollment: 38 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Symptoms of cough, thickened mucus and chest congestion
• Able to produce sputum
• Non Smoker

Exclusion criteria

• Pregnant
• Smokers
• Fever above 101°F
• Any chronic illness

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

38 participants in 2 patient groups, including a placebo group

Guaifenesin

Active Comparator group

Description:

Mucinex 1200mg (Guaifenesin)given as 2, 600mg tablets

Treatment:

Drug: Mucinex

Placebo

Placebo Comparator group

Description:

Given as 2 tablets

Treatment:

Drug: Placebo